Саратовский научно-медицинский ЖУРНАЛ

Prospects of modern methods of diagnosis of renal cancer

Год: 2017, том 13 Номер: №1 Страницы: 068-072
Рубрика: Урология Тип статьи: Обзор
Авторы: Zakharova N.B., Komiagina Yu.M., Ponukalin A.N., Nickolsky Yu.Ye., Korolev A.Yu.
Организация: ФГБОУ ВО Саратовский ГМУ им. В.И. Разумовского Минздрава России

In the researches of recent years it is shown that the cancer of kidneys has been developed against chronic inflammatory process which leads to decrease the activity of a differentiation by the epithelial cells and to strengthening of their proliferation. Further development of a cancer of kidneys is connected with participation of a large number of cytokine and growth factors. Thus tumor cells constantly interact with immune system. These processes lead to tumor associated macrophages which are locally suppressing the antineoplastic immune answer and controlling tumoral angiogenesis to emergence. Now along with a big group of molecular and genetic markers possibility of use of diagnostic and predictive indicators for the effective and personalized treatment of patients with renal cancer the research of tumor associated macrophages and an expression of various proangiogenic factors of an angiogenesis have been considered.

1. Davydov Ml, Aksel' EM. Statistics of malignant tumors in Russia and CIS countries in 2012. Moscow: RONTS, 2014; 226 p.
2. Ljungberg В, Bensalah К, Вех A, et al. Guidelines on renal cell carcinoma, [place unknown]: European association of urology, 2014; 70 p.
3. Garcia JA, Cowey CL, Godley PA. Kidney cellular carcinoma. Curr opin Oncol 2009; 21 (39): 266-271
4. Apanovich NV, Peters MV, Korotaeva AA, et al. Molecular genetic diagnostics of clear cell renal cell carcinoma. Cancer Urology 2016; 12 (4): 16-21
5. Mikhaylenko DS, Alekseev BY, Efremov GD, et al. Genetic characteristics of the nonclear cell renal cancer. Cancer Urology 2016; 12 (3): 14-21
6. Shirokorad VI, Makhson AN, Rusakov IG, et al. Interim results of targeted therapy of patients with metastatic kidney cancer in Moscow (for the period from June 2005 to July 2015). Cancer Urology 2016; 12(2): 14-17
7. Alyaev YuG, Glybochko PV, Grigoryan ZG, et al. Organ-preserving kidney tumor operations. Moscow: GEOTAR-media, 2009; 264 p.
8. Alyaev YuG, Krapivin AA. Resection of kidney for cancer. M.: Medicina, 2001; 223 p.
9. Kattan MW, Sternberg CN, Mehmud F, et al. Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib. Cancer Urology 2015; 11 (4): 16-23
10. Matveev VB, Marilov TV, Junker K. Cytogenetic studies of bilateral renal cell carcinoma. Cancer Urology 2006; (3): 14-18
11. Rini Bl, Campbell SC, Escudier В. Renal cell carcinoma. 2009 Mar 28; 373 (9669): 119-32. https://www.ncbi.nlm.nih.gov/pubmed/19269025
12. Iliopoulos Oh, LeviAP, Jiang C, etal. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93 (20): 10595-9
13. Turcotte S, Chan DA, Sutphin PD, et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cel 2008 Jul 8; 14 (1): 90-102. https:// www.ncbi.nlm.nih.gov/pubmed/18598947
14. Na X, Wu G, Ryan CK, et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003; 170 (2 Pt 1); 588-592
15. Spirina LV, Kondakova IV, Usynin EA, et al. Angiogenesis regulation in renal and bladder cancers. Siberian Journal of oncology 2008; (4): 65-70
16. Juvekar A, Manna S, Ramaswami S, et al. Bortezomib induces nuclear translocation of IkBa resulting in gene-specific suppression of NF-kB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res 2011; 9 (2): 183-194
17. Moorty AK, Savinova OV, Ho JQ, et al. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation independent manner. EMBO J 2006; 25 (9): 1945-1956
18. Spirina LV, Kondakova IV, Usynin EA, et al. Proteasome activity and content of growth factors for cancer of the kidney urinary bladder and endometrium. Russian Journal of Oncology 2010; (1): 23-25
19. Spirina LV, Kondakova IV, Usynin EA, et al. The regulation of expression of transcription factors and vascular endothelial growth factor proteasome system when metastasis of kidney cancer. Journal of N.N. Blokhin Russian Cancer Research Center RAMS, 2012; 23 (1): 27-32
20. Kharchenko ЕР. Carcinogenesis: immune system and immunotherapy. Immunologija 2011; 32 (1): 50-56
21. Eruslanov Е, Stoffs Т, Kim WJ, et al. Expansion of inflammatory CCR8 myeloid cells in patients with renal and urothelial carcinomas. Clin Cancer Res 2013; 19 (7); 1670-80
22. Svistunov AA, Zaharova NB, Emel'janova NV, et al. Laboratory methods of assessment of efficiency of immunomodulatory therapy. Saratov, 2005; 89 p.
23. Grachev AN. Heterogeneity and functional plasticity macrophages of the second type of activation: DSc abstract. M., 2008; 25 p.
24. Bingl L, Brown NJ, Lewis СЕ. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196 (3): 254-65
25. Xu L, Zhu of Y, Chen L, et al. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol 2014; 21 (9): 3142-50. https:// www.ncbi.nlm.nih.gov/pubmed/24615178
26. Malyshev Jul. Matrix reprogramming of immune cages and role of his violation in pathogenesis of tumors. Journal of N. N. Blokhin Russian Cancer Research Center RAMS, 2012; 23 (2): 21-35
27. Cherdantseva ТМ, Bobrov IP, Klimachev VV, et al. Prognostic value of the study of the density disribution tumor-associated of macrophages in kidney. Modern problems of science and education 2016; (3): 21-35
28. Behnes CL, Bremmer of F, Hemmerlein B, et al. Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. Virchows Arch 2014; 464 (2): 191-6. https://www.ncbi.nlm.nih.gov/pubmed/24327306? dopt=Abstract
29. SosninaAV,AutenshlyusAI, Velikaya NV, etal. Cytokine-producing function of peripheral blood cells in colorectal cancer Patients. Medical Immunology 2011; 13 (2-3): 197-204
30. Velikaya NV, Vankhalsky ES, Mikhaylova ES, et al. Antibodies to TNFa and IFNy at the adenokartsinoms of a digestive tract. Russian Allergology Journal 2012; (1): 73-74
31. Li С, Liu В, Dai Z, et al. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biology and Therapy, 2011; 12 (10): 872-880
32. Xu L, Zhu Y, Chen L, et al. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol 2014 Sep; 21 (9): 3142-50. https://www.ncbi.nlm.nih.gov/pubmed/24615178
33. Toge H, Kojimoto Y, Shinka T, et al. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol2009; 16 (10): 801-7
34. Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014; 344; 921-925
35. Sakharov VN, Litvitsky PF. Roles of Different Macrophage Phenotypes in the Pathogenesis of Some Human Diseases. Annals of the Russian Academy of Medical Sciences 2015; 1: 26-31
36. Chen СН, Wang CZ, Wang YH.etal. Effects of Low-Level Laser Therapy on M1 related cytokine expression in monocytes VIAhistone modification. Med Infl 2014; 2014: 625048
37. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196 (3): 254-65. http://onlinelibrary.wiley.eom/doi/10.1002/path.1027/abstract;jse ssionid=A1EA0256EDB08897DCFCBC67D7BA7745.f04t04 38. Li M, Rathmell WK. The current status of biomarkers for renal cell carcinoma, 2011; p. 153-157. http: www.asco.org/FSCOv2/Home/Educftion
39. Banyra OB, Stroy AA, Shulyak AV. Tumor markers in kidney cancer diagnosing. Experimental and clinical urology 2011; (4): 72-78
40. Lukesova S, Kopecky О, Vroblova V, et al. Determination of angiogenic factors in serum by protein array in patients with renal cell carcinoma. Folia Biologica (Praha) 2008: 134-140. 41. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77 (7): 527-543
42. Velikaja NV, Vanhal'skijAV, Mihajlova ES, etal. Antibodies to TNFa and IFNy at digestive tract adenocarcinomas. Russian Allergology Journal 2012; (1): 73-74
43. Kharchenko ЕР. Carcinogenesis: immune system and immunotherapy. Immunology 2011; 32 (1): 50-56
44. Tsimafeyeu I, Demidov L. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease. J Cancer Res The, 2010; 6 (4): 575-7. http://www.cancerjournal.net/text. asp?2010/6/4/575/77084
45. Sergeeva NS, Marshutina NV. New serological tumor-associated markers (S 100, Bone TRAP 5b, UBC, TuM2-PK) in the monitoring of cancer patients. Vestnik Moskovskogo onkologicheskogo obshhestva 2007; (1): 3-4
46. Trapeznikova MF, Glybin PA, Morozov АР, et al. Angiogenic factors in renal cell carcinoma. Oncourology 2008; (4): 82-87
47. Kugler A, Hemmerlein В, Thelen Р, et al. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998 November; 160 (5): 1914-1918
48. Lein M, Jung K, Laube C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000; 85 (6): 801-804
49. Hutson ТЕ, Davis ID, Macheils JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J Clin Oncol 2008; 26: 15
50. Choueiri TK, Xie W, Kollmannsberger CK, et al. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF) — targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration. J Clin Oncol 2010; 28: 15 (suppl; ab-str4524)
51. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011; 29 (18): 2557-64
52. Kim HC, Lee JS, Kim SH, et al. Treatment of Sunitinib of a metastatic kidney and cellular cancer at patients with an illness von Hippel-Lindau. Cancer Res Treat 2013; 45 (4): 349-53
53. Bobkova IN, Kozlovskaja LV, Chebotareva NV. Urinary tests of inflammation and fibrosis in the assessment of progression of chronic glomerulonephritis. Kachestvo zhizni 2006; 15 (4): 19-25
54. Popkov VM, Durnov DA, Zaharova NB, et al. Diagnostic value of angiogenesis rates in renal-cell carcinoma. Medicinskij vestnik Bashkortostana 2015; (3): 184-187
55. Nikolsky YE, Chekhonatskaya ML, Zakharova NB, et al. Magnetic resonance imaging and biomarkers of serum and urine wile diagnostics of kidney cancer. Saratov Journal of Medical Scientific Research 2016; 12 (1): 52-56
56. Lein М, Jung К, Laube С, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000; 85 (6): 801-804
57. Glybochko PV, Durnov DA, Ponukalin AN, et al. Diagnostic significance of metaboliic TUM2PK tumor marker and vascular endothelial growth factor (VEGF) in tumor staging of renal cell carcinoma. Medicinskij vestnik Bashkortostana 2011; 6 (2): 234-239
58. Matveev ВР, ed. Clinical oncourology. М.: Verdana, 2011. 934 p. Russian (Клиническая онкоурология / под ред. Б. П. Матвеева. М.: Вердана, 2011; 934 с.
59. Gorelov Al, Soldatenkov AV, Gorelov DS, et al. Modern aspects of forecasting of cancer of kidney (review of literature). Vestnik S.-Peterb. Un-ta 2008; 11 (4): 153-165
60. Golubnitschaja О, Costigliola V, ЕРМА: General Report and Recommendations in Predictive, Preventive and Personalized Medicine 2012: White Paper of the European Association for Predictive, Preventive and Personalized Medicine. The EPMA J 2012; 3: 14
61. Komohara Y, Hasita H, Ohnishi K, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011; 102: 1424-1431. https:// www.ncbi.nlm.nih.gov/pubmed/21453387.

Прикрепленный файлРазмер
2017_01_068-072.pdf250.05 кб

Голосов пока нет